Showing results (11-20 of 34) with videos related to
Sort By:
Pageof 4
Current Medical Research and Opinion|October 6, 2018
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancerKaren Reckamp, Huamao M Lin, Joice Huang, et al.Journal of Medical Economics|May 25, 2019
Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA studyAriane K Kawata, William R Lenderking, Olabimpe R Eseyin, et al.Lung Cancer (Amsterdam, Netherlands)|March 21, 2021
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L)Maria Rosario Garcia Campelo, Huamao M Lin, Yanyan Zhu, et al.Current Medical Research and Opinion|May 27, 2022
Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomesChristina Soeun Kwon, Huamao M Lin, Victoria Crossland, et al.Cancer Medicine|December 30, 2022
Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutationsYanyan Zhu, Milenka Jean-Baptiste, William R Lenderking, et al.JTO Clinical and Research Reports|September 25, 2023
Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion MutationsSai-Hong Ignatius Ou, Huamao M Lin, Jin-Liern Hong, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2024
Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM databaseKaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, et al.Current Medical Research and Opinion|July 11, 2022
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1LKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.Lung Cancer (Amsterdam, Netherlands)|April 19, 2023
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparisonSai-Hong I Ou, Huamao M Lin, Jin-Liern Hong, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2023
Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLCSai-Hong Ignatius Ou, Jin-Liern Hong, Petros Christopoulos, et al.Pageof 4